IL-37 and IL-38 act as endogenous regulators of CAR-T-associated hyperinflammation in multiple myeloma
New Proteins May Help Control Inflammation in Multiple Myeloma Treatment
This mini-review explores the roles of IL-37 and IL-38 as potential immunoregulatory checkpoints in patients with relapsed/refractory multip…
Two specific proteins, IL-37 and IL-38, may help control dangerous inflammation during CAR-T cell therapy for multiple myeloma.
Talquetamab monotherapy linked to 51% any-grade infection rate in relapsed/refractory myeloma
New data shows infection risks for patients on talquetamab
This systematic review and meta-analysis assessed infection risk with talquetamab in relapsed/refractory multiple myeloma. Pooled rates were…
Patients with relapsed or refractory multiple myeloma may face significant infection risks when treated with the drug talquetamab.
Ciltacabtagene autoleucel is associated with higher non-ICANS neurologic toxicity rates than idecabtagene vicleucel
Trial shows specific risks for some patients with multiple myeloma
This meta-analysis of 4,630 patients evaluates non-ICANS neurologic toxicities (NINTs) following BCMA-directed CAR-T therapy in multiple mye…
New data reveals that one type of CAR-T cell therapy carries a higher risk of nerve issues than others for patients with multiple myeloma.
Bortezomib, cyclophosphamide, and dexamethasone achieved remission in a patient with AL amyloidosis and POEMS syndrome
Treatment shows success for heart failure and rare blood diseases
This case report and literature review describes the treatment of an elderly male with concurrent AL amyloidosis and POEMS syndrome. The pat…
A new look at a complex case reveals how a specific drug combination helped an elderly man with multiple rare conditions.
Indefinite-duration lenalidomide maintenance shows no significant difference in overall survival compared to fixed-duration
Trial compares continuous versus fixed duration lenalidomide for myeloma
This Phase 3 randomized trial of 516 patients with standard-risk newly diagnosed multiple myeloma found that indefinite-duration lenalidomid…
A large trial found that continuing lenalidomide treatment indefinitely did not improve overall survival compared to a fixed two-year plan.
VTE risk models in multiple myeloma show low predictive accuracy, pooled AUC below 0.7
Current risk tools for blood clots in multiple myeloma patients do not work well enough for doctors to trust
This systematic review and meta-analysis of 14 studies evaluated VTE risk prediction models in multiple myeloma. Pooled VTE incidence was 7.…
A review of fourteen studies found that existing models fail to accurately predict blood clots in multiple myeloma patients. The tools used …
Narrative review suggests idiotype-directed CAAR-T therapy remains hypothetical for B-cell malignancies
Idiotype-directed CAAR-T therapy remains a hypothesis for B-cell malignancies
This narrative review discusses idiotype-directed CAAR-T therapy for B-cell malignancies including chronic lymphocytic leukemia and indolent…
A narrative review suggests idiotype-directed CAAR-T therapy is a theoretical option for B-cell cancers, not a current treatment.
Systematic review and meta-analysis of BCMA or GPRC5D bispecific antibodies in relapsed refractory multiple myeloma
New antibodies help some myeloma patients live longer, but infection risks are high
This systematic review and meta-analysis evaluates BCMA- or GPRC5D-directed CD3 bispecific antibodies in 1,900 patients with relapsed or ref…
A review of 1,900 patients found new antibodies helped many with advanced myeloma, yet serious infections and low white blood cell counts re…
FDA Approves Xpovio (selinexor) for Multiple Myeloma and DLBCL
FDA approves new drug Xpovio for certain blood cancers.
The FDA approved Xpovio (selinexor) for multiple myeloma in combination with bortezomib and dexamethasone after at least one prior therapy, …
The FDA approved Xpovio (selinexor) for multiple myeloma and a type of lymphoma called DLBCL. It offers a new option for patients who have t…
Narrative review explores natural products targeting proteasome in multiple myeloma
Natural Products May Help Beat Cancer Drug Resistance
This narrative review summarizes literature up to 2025 on natural products that directly target the proteasome or enhance sensitivity to pro…
New natural compounds may help overcome resistance to powerful cancer drugs, offering hope for patients who stop responding to treatment.
FDA Approves Pomalyst (pomalidomide) for Multiple Myeloma and Kaposi Sarcoma
FDA approves new drug Pomalyst for multiple myeloma and Kaposi sarcoma.
The FDA approved Pomalyst (pomalidomide) for multiple myeloma in combination with dexamethasone after at least two prior therapies, and for …
The FDA approved Pomalyst (pomalidomide) for two conditions: multiple myeloma and Kaposi sarcoma. It offers a new option for patients who ha…
FDA Approves Revlimid (lenalidomide) for Multiple Myeloma and Other Indications
FDA approves Revlimid for several blood cancers and related conditions.
FDA approved Revlimid (lenalidomide) for multiple myeloma (in combination with dexamethasone and as maintenance after auto-HSCT), transfusio…
The FDA approved Revlimid (lenalidomide) for multiple myeloma, certain myelodysplastic syndromes, mantle cell lymphoma, and other lymphomas.…